We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

17 hedge funds and large institutions have $391K invested in Grace Therapeutics in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 0.03% → 0.07% (+0.04%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

35% less funds holding

Funds holding: 26 → 17 (-9)

67% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 12

79% less capital invested

Capital invested by funds: $1.88M → $391K (-$1.49M)

Holders
17
Holders Change
-9
Holders Change %
-34.62%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
4
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$74.5K
2
Jane Street
Jane Street
New York
+$62.1K
3
TSS
Two Sigma Securities
New York
+$43.9K
4
UBS Group
UBS Group
Switzerland
+$4.06K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$2.23K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$573K
2
VF
Virtu Financial
New York
-$211K
3
Squarepoint
Squarepoint
New York
-$53K
4
Morgan Stanley
Morgan Stanley
New York
-$25.1K
5
MMPW
Mitchell McLeod Pugh & Williams
Alabama
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$87K -$573K -29,103 -80%
Citadel Advisors
2
Citadel Advisors
Florida
$73K +$74.5K +3,785 +164%
VF
3
Virtu Financial
New York
$54K -$211K -10,738 -70%
Jane Street
4
Jane Street
New York
$38K +$62.1K +3,153 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$36K – – –
Morgan Stanley
6
Morgan Stanley
New York
$29K -$25.1K -1,273 -34%
TSS
7
Two Sigma Securities
New York
$27K +$43.9K +2,228 New
EDRH
8
Edmond de Rothschild Holding
Switzerland
$25K – – –
SIAP
9
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$10K – – –
UBS Group
10
UBS Group
Switzerland
$9K +$4.06K +206 +38%
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$2K +$2.23K +113 +246%
Bank of America
12
Bank of America
North Carolina
$1K +$1.02K +52 +100%
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$449 -$59 -3 -7%
RE
14
RBC Europe
United Kingdom
$6 – – –
Squarepoint
15
Squarepoint
New York
– -$53K -1,969 Closed
MMPW
16
Mitchell McLeod Pugh & Williams
Alabama
– -$25K -938 Closed
Millennium Management
17
Millennium Management
New York
– -$21K -780 Closed
PAG
18
Private Advisor Group
New Jersey
– -$17K -625 Closed
LPL Financial
19
LPL Financial
California
– -$10K -365 Closed
Commonwealth Equity Services
20
Commonwealth Equity Services
Massachusetts
– -$8K -327 Closed
N
21
Natixis
France
– -$7K -263 Closed
Bank of Montreal
22
Bank of Montreal
Ontario, Canada
– -$6K -227 Closed
ASN
23
Advisory Services Network
Georgia
– -$1K -42 Closed
CAPTRUST Financial Advisors
24
CAPTRUST Financial Advisors
North Carolina
– +$414 +21 New
TRCT
25
Tower Research Capital (TRC)
New York
– +$630 +32 New

GRCE Hedge Fund Activity: Q3 2021 in Review

17 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2021, worth a combined $391K — down 79% from $1.88M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of GRCE and 4 opened new positions — a net loss of 8 holders — while 4 trimmed existing stakes and 4 added.

The largest buyer was Citadel Advisors, adding an estimated $74.5K. The largest seller was Renaissance Technologies, cutting an estimated $573K.

  • 17 institutional investors held Grace Therapeutics (GRCE) as of Q3 2021, down from 26 in Q2 2021.
  • Funds reported $391K of Grace Therapeutics stock for Q3 2021, down 79% quarter-over-quarter.
  • 4 funds opened new Grace Therapeutics positions in Q3 2021 and 12 closed out, a net change of -8 holders.
  • The largest Grace Therapeutics buyer in Q3 2021 was Citadel Advisors, an estimated $74.5K added.
  • The largest Grace Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $573K sold.

Based on aggregated 13F filings for Q3 2021.